

Transfusion in the Intensive Care Unit

Nicole P. Juffermans
Timothy S. Walsh
Editors

 Springer

Transfusion in the Intensive Care Unit

Nicole P. Juffermans • Timothy S. Walsh
Editors

Transfusion in the Intensive Care Unit

 Springer

Editors

Nicole P. Juffermans
Department of Intensive Care L.E.I.C.A.
Academic Medical Center
Amsterdam
The Netherlands

Timothy S. Walsh
MRC Centre for Inflammation Research
University of Edinburgh
The Queens Medical Research Institute
Edinburgh
UK

ISBN 978-3-319-08734-4 ISBN 978-3-319-08735-1 (eBook)
DOI 10.1007/978-3-319-08735-1
Springer Cham Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014950910

© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Contents

1	Introduction	1
	Nicole P. Juffermans and Timothy S. Walsh	
2	Causes of Anemia in Critically Ill Patients	5
	Daniela Ortega and Yasser Sakr	
3	Red Blood Cell Transfusion Trigger in Sepsis	13
	Jean-Louis Vincent	
4	Red Blood Cell Transfusion Trigger in Cardiac Disease	25
	Parasuram Krishnamoorthy, Debabrata Mukherjee, and Saurav Chatterjee	
5	Red Blood Cell Transfusion Trigger in Cardiac Surgery	35
	Gavin J. Murphy, Nishith N. Patel, and Jonathan A.C. Sterne	
6	Red Blood Cell Transfusion Trigger in Brain Injury	45
	Shane W. English, Dean Fergusson, and Lauralyn McIntyre	
7	Red Blood Cell Transfusion in the Elderly	59
	Matthew T. Czaja and Jeffrey L. Carson	
8	ScvO₂ as an Alternative Transfusion Trigger	71
	Szilvia Kocsi, Krisztián Táncoz, and Zsolt Molnár	
9	Alternatives to Red Blood Cell Transfusion	77
	Howard L. Corwin and Lena M. Napolitano	
10	Blood-Sparing Strategies in the Intensive Care Unit	93
	Andrew Retter and Duncan Wyncoll	
11	Massive Transfusion in Trauma	101
	Daniel Frith and Karim Brohi	
12	Transfusion in Gastrointestinal Bleeding	121
	Vipul Jairath	
13	Platelet Transfusion Trigger in the Intensive Care Unit	139
	D. Garry, S. Mckechnie, and S.J. Stanworth	

14 FFP Transfusion in Intensive Care Medicine	151
David Hall and Timothy S. Walsh	
15 Transfusion-Related Acute Lung Injury	161
Alexander P.J. Vlaar and Nicole P. Juffermans	
16 Transfusion-Associated Circulatory Overload	171
Leanne Clifford and Daryl J. Kor	
Index	183

Nicole P. Juffermans and Timothy S. Walsh

Critically ill patients are frequently transfused, with 40–50 % of patients receiving a red blood cell transfusion during their stay in the intensive care unit (ICU) [1].

Current red blood cell transfusion practice in the ICU has largely been shaped by a landmark trial published in 1999, which taught us that a restrictive transfusion trigger is well tolerated in the critically ill and of particular benefit in the young and less severely ill [2]. Following this trial, a restrictive trigger has been widely adopted [3–5]. Nevertheless, transfusion rates in the ICU remain high, rendering blood transfusion part of everyday practice in the ICU.

Red blood cell transfusion rates in the ICU are high because many patients suffer moderately to severe anemia. Anemia is a hallmark of critical illness, occurring in up to 90 % of patients. The cause of anemia is multifactorial, but the presence of inflammation is an important contributor. As anemia usually develops early in the course of critical illness, the term “anemia of inflammation” has become interchangeable with the term “anemia of chronic disease,” which may better describe the critically ill patient population. Transfusion of fresh frozen plasma (FFP) is also common practice in the ICU, with estimates of 12–60 % of patients receiving plasma during their stay [6, 7]. Frequent transfusion of FFP is due to a large proportion of patients with a coagulopathy and/or patients who experience or are considered at risk for bleeding [7, 8]. The reported wide variation in the practice of FFP transfusion suggests clinical uncertainty about best practice [7–9].

N.P. Juffermans (✉)

Department of Intensive Care Medicine, Academic Medical Center,
Room G3-206, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.),
Academic Medical Center, Amsterdam, The Netherlands

e-mail: n.p.juffermans@amc.uva.nl

T.S. Walsh

Department of Anaesthetics, Critical Care and Pain Medicine,
Edinburgh University, Edinburgh, UK

Similarly, thrombocytopenia is a prevalent, occurring in up to 30 %, triggering platelet transfusion in 10 % of patients [7]. Taken together, transfusion of blood products is one of the most common therapies in the ICU.

It is increasingly clear that an association between transfusion and adverse outcome exists, including the occurrence of lung injury, multiple organ failure, thromboembolic events, and nosocomial infections. These associations are not restricted to the critically ill patient population, but the relation between blood transfusion and adverse outcome seems most apparent in this group [10], suggesting that critically ill patients may have specific features which render them susceptible to possible detrimental effects of a blood transfusion. Thereby, ICU physicians are advised to be restrictive with transfusion [11, 12]. A challenge in understanding the optimum use of blood products in the critically ill is delineating whether this association is causative or simply a result of the residual confounding and bias by indication which influences observational studies.

The dark side of these efforts to adhere to a restrictive practice to mitigate adverse effects of blood transfusion may be under-transfusion, which may be particularly relevant to the correction of anemia with red blood cells. Multiple studies have shown an association between anemia and adverse outcome, in a wide variety of patients, including brain injury and myocardial infarction [11, 13–16]. Thereby, both anemia and transfusion are unwanted conditions, posing a challenge to the treating physician, who wonders what to do with a low hemoglobin level. Transfuse, not transfuse, or consider an alternative treatment?

These observations underline the need for a careful assessment of whether risks of transfusion outweigh the perceived benefit. In other words, can a particular patient tolerate anemia? Tolerance to anemia differs between different populations, depending on physiologic state, diagnosis, comorbidity, and cause of anemia. Although guidelines advise taking age and other physiologic variables into consideration in the decision to transfuse [11, 12], studies which have compared different triggers in different settings have been limited, and the overall evidence base is weak. Red cell transfusion, in particular, is still strongly influenced by the landmark “TRICC” trial and applied in a “one-size-fits-all” fashion. This despite changes to the red cell product in many countries (the introduction of leucodepletion), improvements in other aspects of critical care (which might change the “signal-to-noise” ratio associated with blood transfusion), and the fact that the original trial was underpowered and stopped early having reached only half of the intended sample size.

In the last decade, several clinical trials have studied red blood cell transfusion triggers in various ICU patient populations. Also, large and well-conducted trials have been performed in specific conditions which are frequently present in the critically ill, including myocardial infarction or gastrointestinal bleeding. These studies empower the physician to take a personalized approach towards transfusion of red blood cells and are discussed in this book.

Also for FFP, the horizon has lightened up with data on efficacy of FFP in traumatic bleeding, which suggest that in traumatic bleeding, FFP should be given earlier and in greater quantities. An important trial on platelet transfusion to prevent bleeding was also recently published, although from the hemoncology setting.

A handbook which summarizes results from these recent trials on transfusion triggers was lacking. Here, we present a practical handbook on transfusion triggers in the ICU, which can be used in everyday practice. Chapters are written by leading researchers in the field from all over the globe. This book aims to facilitate a more tailor-made approach in specific ICU patient populations. In the absence of large randomized trials in specific subpopulations, such an approach will help decrease under-transfusion as well as unnecessary over-transfusion, thereby increasing efficacy of the use of available blood. We hope this book will help clinicians make rational individualized decisions, avoiding a “one-size-fits-all” transfusion practice and promoting personalized therapy. This book also provides practical information on alternatives to red blood cell transfusion, as well as means to limit loss of blood by phlebotomy. The most common adverse events are also discussed, again with a practical focus on management at the bedside.

Optimal care for a patient always requires clinical judgment of the treating physician, because individual patients may not fall within a clear recommendation. Nevertheless, we hope this book may support physicians in their everyday care for the critically ill.

References

1. Vincent JL, Piagnerelli M. Transfusion in the intensive care unit. *Crit Care Med.* 2006;34(5 Suppl):S96–101.
2. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med.* 1999;340(6):409–17.
3. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: Anemia and blood transfusion in the critically ill – current clinical practice in the United States. *Crit Care Med.* 2004; 32(1):39–52.
4. Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. *Anesthesiology.* 2008;108(1):31–9.
5. Vlaar AP, in der Maur AL, Binnekade JM, Schultz MJ, Juffermans NP. Determinants of transfusion decisions in a mixed medical-surgical intensive care unit: a prospective cohort study. *Blood Transfus.* 2009;7(2):106–10.
6. Reiter N, Wesche N, Perner A. The majority of patients in septic shock are transfused with fresh-frozen plasma. *Dan Med J.* 2013;60(4):A4606.
7. Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. *Crit Care.* 2011;15(2):R108.
8. Vlaar AP, in der Maur AL, Binnekade JM, Schultz MJ, Juffermans NP. A survey of physicians’ reasons to transfuse plasma and platelets in the critically ill: a prospective single-centre cohort study. *Transfus Med.* 2009;19(4):207–12.
9. Watson DM, Stanworth SJ, Wyncoll D, McAuley DF, Perkins GD, Young D, Biggin KJ, Walsh TS. A national clinical scenario-based survey of clinicians’ attitudes towards fresh frozen plasma transfusion for critically ill patients. *Transfus Med.* 2011;21(2):124–9.
10. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. *Crit Care Med.* 2008;36(9):2667–74.

11. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, Hebert PC, Anderson GL, Bard MR, Bromberg W, Chiu WC, Cipolle MD, Clancy KD, Diebel L, Hoff WS, Hughes KM, Munshi I, Nayduch D, Sandhu R, Yelon JA. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. *Crit Care Med.* 2009;37(12):3124–57.
12. Retter A, Wyncoll D, Pearse R, Carson D, McKechnie S, Stanworth S, Allard S, Thomas D, Walsh T. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. *Br J Haematol.* 2013;160(4):445–64.
13. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. *JAMA Intern Med.* 2013;173(2):132–9.
14. Oddo M, Levine JM, Kumar M, Iglesias K, Frangos S, Maloney-Wilensky E, Le Roux PD. Anemia and brain oxygen after severe traumatic brain injury. *Intensive Care Med.* 2012;38(9):1497–504.
15. Sekhon MS, McLean N, Henderson WR, Chittock DR, Griesdale DE. Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury. *Crit Care.* 2012;16(4):R128.
16. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santalo M, Muniz E, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med.* 2013; 368(1):11–21.

Daniela Ortega and Yasser Sakr

Abstract

Anemia is a common occurrence in critically ill patients and is associated with considerable morbidity and worse outcomes. The prevalence of anemia among critically ill patients is influenced by factors that include patient case mix, illness severity, and preexisting comorbidity. Several factors may lead to anemia in critically ill patients and the etiology of anemia in individual patients is commonly multifactorial and may be related either to the underlying disease process or occur as a consequence of diagnostic or therapeutic interventions in the intensive care unit (ICU). Anemia of chronic disease is the most important form of anemia related to preexisting morbidity on admission to ICU. Blood loss considerably contributes to the development of anemia during the ICU stay. Other factors that may lead to anemia in critically ill patients include reduced red blood cell (RBC) production, abnormal RBC maturation, decreased RBC survival, or excessive RBC destruction. This chapter reviews the possible etiologic factors of anemia with a special emphasis on the underlying pathophysiology of these factors.

2.1 Introduction

Anemia is a common occurrence in critically ill patients and is associated with considerable morbidity and worse outcomes [1, 2]. The prevalence of anemia among critically ill patients is influenced by factors that include patient case mix, illness severity, and preexisting comorbidity [3]. A cohort study of 3,534 patients admitted

D. Ortega, MD • Y. Sakr, MD, PhD (✉)
Department of Anesthesiology and Intensive Care, Friedrich-Schiller-University Hospital,
Erlanger Allee 103, 07743 Jena, Germany
e-mail: yasser.sakr@med.uni-jena.de




Fig. 2.1 Schematic diagram demonstrating the possible causes of anemia in critically ill patients

to Western European intensive care units (ICUs) reported that 63 % of patients had a hemoglobin concentration <12 g/dl at ICU admission and 29 % had hemoglobin concentrations <10 g/dl [1]. In this study, anemia was more frequent and severe in older patients. During the ICU stay, hemoglobin concentrations decreased on average by 0.66 g/dl/day for the first 3 days and by 0.12 g/dl/day thereafter. An early rapid decrease in hemoglobin values was also reported in a prospective observational single-center cohort study of patients present for more than 24 h in the ICU [4]. Another study found that 77.4 % of all ICU survivors were anemic (defined as hemoglobin concentration <13 g/dl for men and <11.5 g/dl for women) when discharged home from the hospital and 32.5 % had a hemoglobin concentration <10 g/dl. Fifty percent of patients who spent >7 days in the ICU had hemoglobin concentrations <10 g/dl at hospital discharge [5].

Several factors contribute to anemia in critically ill patients (Fig. 2.1). The etiology of anemia in individual patients is commonly multifactorial [3] and may be related either to the underlying disease process or occur as a consequence of diagnostic or therapeutic interventions in the ICU. The most important factors are discussed in the following section.

2.2 Anemia of Chronic Disease

Anemia of chronic disease (ACD) is a common form of anemia that occurs in patients suffering from longstanding and/or advanced chronic disease [6]. Patients can be considered to have ACD when they present the following: (1) a chronic infection or inflammation, autoimmune disease or malignancy or renal disease; (2) a hemoglobin concentration <13 g/dl for men and <12 g/dl for women; and (3) a low transferrin saturation (<20 %), but normal or increased serum ferritin concentration (>100 ng/ml) or low serum ferritin concentration (30–100 ng/ml) [7]. Measurement of reticulocyte counts, endogenous erythropoietin (EPO) secretion (ratio of observed EPO to expected EPO), and serum creatinine (glomerular filtration) may be helpful in defining the cause of ACD. Because critically ill patients often have multiple comorbidities, this type of anemia may contribute to the prevalent low hemoglobin levels described on admission to the ICU in large epidemiologic studies [1, 2]. Fifty percent of patients admitted to ICUs with hemoglobin concentrations <10 g/dl have a history of either acute bleeding or ACD [1].

2.3 Blood Loss

Blood loss is a significant cause of anemia in intensive care patients. Potential sources of blood loss are diagnostic blood sampling and hemorrhage.

2.3.1 Phlebotomy Losses

Early studies found that, on average, a critically ill patient lost 1–2 units of blood through blood sampling during their hospital stay or up to 30 % of the total blood transfused in the ICU [8]. More recent data indicate that 30–40 ml are removed in blood samples per 24 h, with more blood sampled in sicker patients and those receiving renal replacement therapy [1]. Laboratory testing plays a critical role in diagnosis and guiding appropriate patient management during critical illness; a recent study in trauma patients suggested that laboratory testing is becoming more frequent with an increase in the number of blood tests ordered and blood volumes drawn in 2009 compared to 2004 [9].

2.3.2 Hemorrhagic Losses

There are many potential sources of bleeding in critically ill patients. Gastrointestinal bleeding may play a less important role than in the past with more widespread use of prophylaxis and rapid resuscitation and management, but some groups of patients, for example, those receiving mechanical ventilation or with coagulopathy and renal failure [10], remain at higher risk of bleeding. A recent study in Australia and New Zealand reported that bleeding was the reason for transfusion in 46 % of transfusion events [11].

2.4 Reduced Red Cell Production

Red blood cell (RBC) production, or erythropoiesis, occurs in the bone marrow and is controlled by EPO, a 165 amino acid glycoprotein hormone produced by interstitial fibroblasts in the kidney [12]. EPO promotes the proliferation and differentiation of early erythroid progenitors in the bone marrow into mature erythrocytes. Effective erythropoiesis requires various factors, including iron, zinc, folate and vitamin B₁₂, thyroxine, androgens, cortisol, and catecholamines [13]. RBC formation occurs at a basal rate of 15–20 ml/day under physiological conditions but can increase up to tenfold after hemolysis or heavy blood loss [14].

2.4.1 Substrate Deficiency

Iron deficiency may play a major role in decreased RBC production in critically ill patients. Around 70 % of the iron in the body is located within RBC hemoglobin. The body absorbs 1–2 mg of dietary iron a day, which balances the iron lost through shed intestinal mucosal cells, menstruation, and other blood loss. Regulation of the absorption of dietary iron from the duodenum plays a critical role in iron homeostasis [15]. Most of the dietary iron is absorbed at the apical surface of duodenal enterocytes. Iron released into the circulation then binds to transferrin, which has two binding sites for one atom of iron each; about 30–40 % of these sites are occupied in normal physiological conditions. Transferrin carrying iron interacts with specific surface receptors (transferrin-receptor 1, TfR1) to form transferrin-receptor complexes that are endocytosed into the target cells. Erythroid precursors express high levels of TfR1 to ensure the uptake of iron.

Iron homeostasis can be disturbed by inflammation. Activation of the immune and inflammatory systems inhibits iron absorption and iron recirculation and increases ferritin synthesis and iron storage [16]. These effects lead to hypoferrremia, iron-restricted erythropoiesis, and finally to mild to moderate anemia [17, 18].

Theoretically, vitamin B12 and folate deficiency may play a role in the development of anemia in ICU patients. However, the few data that are available suggest that these vitamins do not limit RBC production in most anemic critically ill patients [19].

2.4.2 Inappropriately Low Circulating Erythropoietin Concentrations

The normal response to anemia is an increase in EPO release from the kidneys. Values of circulating EPO concentrations have been established in otherwise healthy patients with various degrees of anemia [7]. Using these data as references for an appropriate response to anemia, many studies have shown that critically ill patients have inappropriately low EPO concentrations for their degree of anemia [20, 21]. The blunted EPO response during critical illness probably results from inhibition of the EPO gene by inflammatory cytokines [22, 23].

2.5 Abnormal RBC Maturation

Critical illness is often associated with increased concentrations of inflammatory cytokines, such as tumor necrosis factor (TNF)- α , interleukin (IL)-1, and IL-6, particularly during sepsis. Many of these cytokines have been shown to directly inhibit RBC formation. Other circulating factors, such as interferon- γ , have been shown to induce apoptosis of erythroid precursors in experimental studies. In addition to the relative deficiency of circulating EPO and decreased iron availability, these factors help explain the poor erythroid response to anemia in critically ill patients. Bone marrow hyporeactivity is also suggested by the fact that reticulocyte counts are usually not increased in anemic critically ill patients unless pharmacological doses of EPO are being administered to stimulate erythropoiesis [19, 24].

2.6 Reduced Red Cell Survival

In healthy humans, erythrocytes have a lifespan of approximately 100–120 days. Normal RBC aging leads to changes in membrane characteristics with decreased deformability, loss of volume and surface area, increased cell density and viscosity, and alterations in the intracellular milieu [13]. These changes result in a decrease in cellular energy levels, increased hemoglobin-oxygen affinity, reduced ability to repair oxidant injury, and decreased ability of the cells to deform when passing through the microvasculature [25]. These changes also indicate that the RBCs are ready for removal by the spleen and reticuloendothelial system. Other determinants of RBC survival include the premature death of mature RBCs (eryptosis) and the removal of RBCs just released from the marrow (neocytolysis). Eryptosis, an apoptosis-like process, is thought to be, in part, triggered by excessive oxidant RBC injury and is inhibited by EPO, which therefore prolongs the lifespan of circulating RBCs [26]. Excessive eryptosis may lead to the development of anemia [27]. Neocytolysis is a process initiated by a sudden decrease in EPO levels by which young circulating RBCs are selectively removed from the circulation [28]. Eryptosis and neocytolysis act at different points in the lifespan of the RBC and thus provide a flexible means of controlling the regulation of total RBC mass.

The normal aging alterations in RBC rheology may occur earlier in critically ill patients, which may have clinical implications [29]. It is likely that critical illness and sepsis, in particular, reduce RBC lifespan, but there is as yet no direct evidence to support this. Experimental data have shown that inflammatory mediators, such as TNF- α and IL-1, can decrease erythrocyte survival time in other settings [30], and oxidative stress has been shown to induce premature apoptosis in RBCs [31].

2.7 Increased RBC Destruction

Hemolysis may be associated with several pathologic conditions, including hemoglobinopathies, hemolytic anemias, bacterial infections, malaria, and trauma. Hemolysis can also occur in conditions in which mechanical forces can lead to RBC

rupture, such as surgical procedures, hemodialysis, and blood transfusion. Extracorporeal circuits may lead to complete RBC destruction or cause less severe damage resulting in altered rheological properties. Hemolysis results in release of free plasma hemoglobin and heme, which are toxic to the vascular endothelium [32]. Although most RBC destruction in standard cardiopulmonary bypass procedures can be managed by the endogenous clearing mechanisms, in some cases, for example, in extensive surgery and with prolonged support, higher degrees of hemolysis may occur, and levels of plasma free hemoglobin can rise substantially. These patients are especially susceptible to the toxic influence of un-scavenged RBC constituents and the loss of RBC rheological properties [33].

Hypersplenism may also lead to excessive RBC destruction and is characterized by a significant reduction in one or more of the cellular elements of the blood in the presence of normocellular or hypercellular bone marrow and splenomegaly [34]. In patients with chronic liver disease, hypersplenism secondary to portal hypertension is an important cause of anemia. The main characteristics of hypersplenism are related to the presence of pancytopenia; hemolytic anemia occurs because of intrasplenic destruction of erythrocytes [35].

2.8 Hemodilution

Critically ill patients frequently develop intravascular hypovolemia requiring fluid resuscitation. Current management involves administering crystalloid or colloid solutions during resuscitation and withholding RBC transfusion unless there is severe hemorrhage. The resultant relatively modest hemodilution contributes to the rapid decrease in hemoglobin concentrations seen early after ICU admission in many critically ill patients [36] and can cause anemia without decreasing RBC mass.

2.9 Conclusion

Anemia is a common occurrence in critically ill patients and is associated with considerable morbidity and worse outcomes. The etiology of anemia in individual patients is commonly multifactorial. Understanding the possible etiologic factors of anemia is crucial to prevent its occurrence and identify the appropriate therapeutic approach to treat this condition in critically ill patients.

References

1. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, et al. Anemia and blood transfusion in critically ill patients. *JAMA*. 2002;288:1499–507.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, et al. The CRIT Study: Anemia and blood transfusion in the critically ill – current clinical practice in the United States. *Crit Care Med*. 2004;32:39–52.
3. Vincent JL, Sakr Y, Creteur J. Anemia in the intensive care unit. *Can J Anaesth*. 2003;50:S53–9.

4. Chohan SS, McArdle F, McClelland DB, Mackenzie SJ, Walsh TS. Red cell transfusion practice following the transfusion requirements in critical care (TRICC) study: prospective observational cohort study in a large UK intensive care unit. *Vox Sang.* 2003;84:211–8.
5. Walsh TS, Saleh EE, Lee RJ, McClelland DB. The prevalence and characteristics of anaemia at discharge home after intensive care. *Intensive Care Med.* 2006;32:1206–13.
6. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med.* 2005;352:1011–23.
7. Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. *Blood.* 1993;81:1067–76.
8. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. *N Engl J Med.* 1986;314:1233–5.
9. Branco BC, Inaba K, Doughty R, Brooks J, Barmparas G, et al. The increasing burden of phlebotomy in the development of anaemia and need for blood transfusion amongst trauma patients. *Injury.* 2012;43:78–83.
10. Cook D, Heyland D, Griffith L, Cook R, Marshall J, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. *Crit Care Med.* 1999;27:2812–7.
11. Westbrook A, Pettit V, Nichol A, Bailey MJ, Syres G, et al. Transfusion practice and guidelines in Australian and New Zealand intensive care units. *Intensive Care Med.* 2010;36:1138–46.
12. Sinclair AM. Erythropoiesis stimulating agents: approaches to modulate activity. *Biologics.* 2013;7:161–74.
13. Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in critical illness: insights into etiology, consequences, and management. *Am J Respir Crit Care Med.* 2012;185:1049–57.
14. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. *J Clin Invest.* 1969;48:454–60.
15. Andrews NC. Forging a field: the golden age of iron biology. *Blood.* 2008;112:219–30.
16. Munoz M, Villar I, Garcia-Erce JA. An update on iron physiology. *World J Gastroenterol.* 2009;15:4617–26.
17. Franke A, Lante W, Fackeldey V, Becker HP, Kurig E, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *Eur J Cardiothorac Surg.* 2005;28:569–75.
18. Cook JD. Diagnosis and management of iron-deficiency anaemia. *Best Pract Res Clin Haematol.* 2005;18:319–32.
19. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. *J Crit Care.* 2001;16:36–41.
20. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, et al. Erythropoietin response is blunted in critically ill patients. *Intensive Care Med.* 1997;23:159–62.
21. Elliot JM, Virankabutra T, Jones S, Tanudsintum S, Lipkin G, et al. Erythropoietin mimics the acute phase response in critical illness. *Crit Care.* 2003;7:R35–40.
22. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. *Life Sci.* 1992;50:301–8.
23. Corwin HL, Krantz SB. Anemia of the critically ill: “acute” anemia of chronic disease. *Crit Care Med.* 2000;28:3098–9.
24. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. *Crit Care Med.* 2000;28:2773–8.
25. Ott P. Membrane acetylcholinesterases: purification, molecular properties and interactions with amphiphilic environments. *Biochim Biophys Acta.* 1985;822:375–92.
26. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, et al. Inhibition of erythrocyte cation channels by erythropoietin. *J Am Soc Nephrol.* 2003;14:2750–7.
27. Lang F, Lang KS, Lang PA, Huber SM, Wieder T. Mechanisms and significance of eryptosis. *Antioxid Redox Signal.* 2006;8:1183–92.
28. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. *Cell Physiol Biochem.* 2005;15:245–50.

29. Reggiori G, Occhipinti G, De GA, Vincent JL, Piagnerelli M. Early alterations of red blood cell rheology in critically ill patients. *Crit Care Med.* 2009;37:3041–6.
30. Scharfe M, Fink MP. Red blood cell physiology in critical illness. *Crit Care Med.* 2003;31:S651–7.
31. Lang KS, Durantón C, Poehlmann H, Myssina S, Bauer C, et al. Cation channels trigger apoptotic death of erythrocytes. *Cell Death Differ.* 2003;10:249–56.
32. Vinchi F, Tolosano E. Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis. *Oxid Med Cell Longev.* 2013;2013:396527.
33. Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. *J Extra Corpor Technol.* 2008;40:257–67.
34. Jeker R. Hypersplenism. *Ther Umsch.* 2013;70:152–6.
35. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. *World J Gastroenterol.* 2009;15:4653–8.
36. Van PY, Riha GM, Cho SD, Underwood SJ, Hamilton GJ, et al. Blood volume analysis can distinguish true anemia from hemodilution in critically ill patients. *J Trauma.* 2011;70:646–51.